Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 6 | 2014 | 778 | 0.820 |
Why?
|
| Cryosurgery | 3 | 2010 | 53 | 0.500 |
Why?
|
| Prostatic Hyperplasia | 3 | 2008 | 25 | 0.440 |
Why?
|
| Salvage Therapy | 2 | 2010 | 82 | 0.400 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2008 | 32 | 0.390 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 475 | 0.390 |
Why?
|
| Prostatism | 1 | 2008 | 1 | 0.330 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2008 | 2 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 510 | 0.330 |
Why?
|
| Prostate-Specific Antigen | 4 | 2016 | 138 | 0.320 |
Why?
|
| Management Information Systems | 1 | 2006 | 4 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 444 | 0.260 |
Why?
|
| Academic Medical Centers | 1 | 2006 | 281 | 0.240 |
Why?
|
| Education, Medical, Graduate | 1 | 2006 | 214 | 0.240 |
Why?
|
| Program Evaluation | 1 | 2006 | 502 | 0.240 |
Why?
|
| Curriculum | 1 | 2006 | 575 | 0.210 |
Why?
|
| Algorithms | 1 | 2007 | 1194 | 0.200 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 99 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2006 | 596 | 0.180 |
Why?
|
| Biopsy | 2 | 2014 | 539 | 0.170 |
Why?
|
| Prostatectomy | 2 | 2014 | 87 | 0.170 |
Why?
|
| Kidney Neoplasms | 2 | 2010 | 206 | 0.150 |
Why?
|
| Mass Screening | 1 | 2003 | 837 | 0.150 |
Why?
|
| Brachytherapy | 2 | 2010 | 79 | 0.150 |
Why?
|
| Fluoroquinolones | 1 | 2016 | 49 | 0.130 |
Why?
|
| Carcinoma, Ductal | 1 | 2014 | 14 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 110 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2014 | 86 | 0.120 |
Why?
|
| Aged | 8 | 2016 | 14842 | 0.110 |
Why?
|
| Male | 12 | 2016 | 37281 | 0.110 |
Why?
|
| Penile Neoplasms | 1 | 2011 | 11 | 0.100 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 39 | 0.100 |
Why?
|
| Indium Radioisotopes | 1 | 2010 | 19 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 349 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 36 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 137 | 0.090 |
Why?
|
| Humans | 14 | 2016 | 68525 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 799 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2014 | 7028 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 648 | 0.080 |
Why?
|
| Goserelin | 1 | 2008 | 6 | 0.080 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2008 | 32 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 63 | 0.080 |
Why?
|
| Testosterone | 1 | 2008 | 96 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2010 | 237 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 955 | 0.080 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2007 | 14 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 46 | 0.070 |
Why?
|
| Integrated Advanced Information Management Systems | 1 | 2006 | 2 | 0.070 |
Why?
|
| Professional Staff Committees | 1 | 2006 | 11 | 0.070 |
Why?
|
| Organizational Case Studies | 1 | 2006 | 53 | 0.070 |
Why?
|
| Systems Integration | 1 | 2006 | 30 | 0.070 |
Why?
|
| Social Responsibility | 1 | 2006 | 39 | 0.070 |
Why?
|
| Middle Aged | 9 | 2016 | 21119 | 0.070 |
Why?
|
| Organizational Objectives | 1 | 2006 | 70 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 110 | 0.070 |
Why?
|
| Accreditation | 1 | 2006 | 72 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 581 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 2222 | 0.060 |
Why?
|
| Finasteride | 1 | 2003 | 2 | 0.060 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2003 | 9 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2011 | 7264 | 0.060 |
Why?
|
| Doxazosin | 1 | 2003 | 20 | 0.060 |
Why?
|
| Palpation | 1 | 2003 | 21 | 0.060 |
Why?
|
| Software | 1 | 2006 | 418 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 375 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 186 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 3256 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2006 | 657 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 659 | 0.050 |
Why?
|
| South Carolina | 1 | 2006 | 2750 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 772 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 4843 | 0.040 |
Why?
|
| Patient Selection | 1 | 2002 | 592 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 929 | 0.040 |
Why?
|
| Prostatitis | 1 | 2016 | 10 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1851 | 0.030 |
Why?
|
| Palladium | 1 | 2010 | 12 | 0.020 |
Why?
|
| Time Factors | 2 | 2010 | 4655 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2010 | 62 | 0.020 |
Why?
|
| Computer Systems | 1 | 2010 | 42 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2010 | 40 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 119 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 125 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 191 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 216 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2011 | 200 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 536 | 0.020 |
Why?
|
| Anesthesia | 1 | 2010 | 120 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 500 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 3702 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 2093 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 805 | 0.020 |
Why?
|
| Postal Service | 1 | 2002 | 19 | 0.010 |
Why?
|
| Mass Media | 1 | 2002 | 29 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 1039 | 0.010 |
Why?
|
| Disease Progression | 1 | 2003 | 1037 | 0.010 |
Why?
|
| Adult | 2 | 2010 | 21375 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 1737 | 0.010 |
Why?
|
| United States | 1 | 2011 | 7335 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2323 | 0.010 |
Why?
|
| Female | 1 | 2007 | 38015 | 0.000 |
Why?
|